Literature DB >> 32782353

Antibody response to SARS-CoV-2 - sustained after all?

Ewoud B Compeer1, Lion F K Uhl2.   

Abstract

Entities:  

Year:  2020        PMID: 32782353      PMCID: PMC7418089          DOI: 10.1038/s41577-020-00423-9

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


× No keyword cloud information.
Recent studies have indicated that antibody responses to SARS-CoV-2 drop significantly within 2 months. In this preprint, Wu et al. analysed antibody responses in 349 individuals who were among the first to become infected with SARS-CoV-2. All antiviral antibody titres significantly increased in the first weeks after disease onset, followed by a contraction phase, where IgM became undetectable at around week 10–13. Importantly, although Spike-targeted IgG (IgG-S) declined over time, it remained detectable at relatively high levels until the end of the 6-month study period. IgG-S titres correlated closely with neutralizing capacity, although exact correlates of protection for SARS-CoV-2 are still elusive. These results suggest that antibody responses in symptomatic patients with COVID-19 follow a prototypical progression and result in a sustained memory response, suggesting long-term protective immunity.
  1 in total

Review 1.  Seclusion and restraint: what we need to know.

Authors:  E Walsh; B P Randell
Journal:  J Child Adolesc Psychiatr Nurs       Date:  1995 Jan-Mar
  1 in total
  3 in total

1.  Alterations in T and B cell function persist in convalescent COVID-19 patients.

Authors:  Halima A Shuwa; Tovah N Shaw; Sean B Knight; Kelly Wemyss; Flora A McClure; Laurence Pearmain; Ian Prise; Christopher Jagger; David J Morgan; Saba Khan; Oliver Brand; Elizabeth R Mann; Andrew Ustianowski; Nawar Diar Bakerly; Paul Dark; Christopher E Brightling; Seema Brij; Timothy Felton; Angela Simpson; John R Grainger; Tracy Hussell; Joanne E Konkel; Madhvi Menon
Journal:  Med (N Y)       Date:  2021-03-31

2.  Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.

Authors:  Tiandan Xiang; Boyun Liang; Yaohui Fang; Sihong Lu; Sumeng Li; Hua Wang; Huadong Li; Xiaoli Yang; Shu Shen; Bin Zhu; Baoju Wang; Jun Wu; Jia Liu; Mengji Lu; Dongliang Yang; Ulf Dittmer; Mirko Trilling; Fei Deng; Xin Zheng
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

3.  Roles and Interplay of SARS-CoV-2 Serology With Clinical Stages of Disease in COVID-19.

Authors:  Monica Mutyala; Ruhma Ali; Kok Hoe Chan; Aditya Patel; Chrystina Kiwan; Zareh Ekmekjian; Kalyan Koneru; Dhinesh V Reddy; Richard Miller; Maria Szabela; Jihad Slim
Journal:  Cureus       Date:  2021-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.